{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:06:34Z","timestamp":1778677594987,"version":"3.51.4"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.clml.2017.02.015","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T19:00:32Z","timestamp":1501268432000},"page":"S62-S74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"S","title":["Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms"],"prefix":"10.1016","volume":"17","author":[{"given":"Umang","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajyalakshmi","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyur P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.02.015_bib1","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.015_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World\u00a0Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib4","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.015_bib5","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ejh.12578","article-title":"Molecular diagnostics of myeloproliferative neoplasms","volume":"95","author":"Langabeer","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2017.02.015_bib7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib9","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.clml.2017.02.015_bib10","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3324\/haematol.13224","article-title":"Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis","volume":"94","author":"Schnittger","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.02.015_bib12","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.015_bib13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2017.02.015_bib14","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1182\/blood-2014-06-583161","article-title":"Presence of calreticulin mutations in JAK2-negative polycythemia vera","volume":"124","author":"Broseus","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib15","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/leu.2014.49","article-title":"Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"28","author":"Broseus","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/bjh.12969","article-title":"JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort","volume":"167","author":"McGaffin","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.02.015_bib17","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMc1413718","article-title":"A\u00a0CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm","volume":"372","author":"Cabagnols","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.015_bib18","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib19","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib20","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3324\/haematol.2014.107482","article-title":"Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations","volume":"99","author":"Andrikovics","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.02.015_bib21","series-title":"NCCN Clinical Practice Guideline in Oncology: Myeloproliferative Neoplasms, Version 1.2017","year":"2016"},{"key":"10.1016\/j.clml.2017.02.015_bib22","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.015_bib23","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","article-title":"CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib24","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib25","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib26","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib27","first-page":"110","article-title":"Acute myeloid leukemia with recurrent genetic abnormalities","volume":"Vol 2","author":"Arber","year":"2008"},{"key":"10.1016\/j.clml.2017.02.015_bib28","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.015_bib29","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2010.31.1175","article-title":"Unraveling the molecular pathophysiology of myelodysplastic syndromes","volume":"29","author":"Bejar","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.015_bib30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib31","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2013-09-381665","article-title":"The genetic basis of myelodysplasia and its clinical relevance","volume":"122","author":"Cazzola","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib32","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib33","series-title":"NCCN Clinical Practice Guideline in Clinical Oncology: Acute Myeloid Leukemia, Version 2.2016","year":"2016"},{"key":"10.1016\/j.clml.2017.02.015_bib34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1309\/AJCPEI9XU8PYBCIO","article-title":"FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia","volume":"135","author":"Bains","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2017.02.015_bib35","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/ejh.12549","article-title":"Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation","volume":"96","author":"Peng","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2017.02.015_bib37","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","article-title":"Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1","volume":"324","author":"Tahiliani","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.clml.2017.02.015_bib38","doi-asserted-by":"crossref","first-page":"14566","DOI":"10.1073\/pnas.1112317108","article-title":"Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice","volume":"108","author":"Ko","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.clml.2017.02.015_bib39","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1200\/JCO.2009.22.6985","article-title":"Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome","volume":"27","author":"Mohamedali","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.015_bib40","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2007-05-092304","article-title":"Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS\/MPD, and MDS-derived AML","volume":"111","author":"Gondek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib41","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/ng.391","article-title":"Acquired mutations in TET2 are common in myelodysplastic syndromes","volume":"41","author":"Langemeijer","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2017.02.015_bib42","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.015_bib43","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1182\/blood-2009-02-205690","article-title":"Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic\/myeloproliferative neoplasms","volume":"113","author":"Jankowska","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib44","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/leu.2011.326","article-title":"Landscape of TET2 mutations in acute myeloid leukemia","volume":"26","author":"Weissmann","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib45","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1200\/JCO.2010.32.7742","article-title":"TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"29","author":"Metzeler","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.015_bib46","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.015_bib47","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.015_bib48","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1084\/jem.20131144","article-title":"Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders","volume":"210","author":"Muto","year":"2013","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2017.02.015_bib49","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2011.40.7379","article-title":"Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes","volume":"30","author":"Bejar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.015_bib50","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib51","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1038\/bcj.2015.113","article-title":"Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2017.02.015_bib52","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.74.010904.153721","article-title":"Eukaryotic cytosine methyltransferases","volume":"74","author":"Goll","year":"2005","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.clml.2017.02.015_bib53","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/leu.2011.44","article-title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes","volume":"25","author":"Walter","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib54","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.015_bib55","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.24581","article-title":"DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.02.015_bib56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.path.2015.10.004","article-title":"Genetic testing in acute myeloid leukemia and myelodysplastic syndromes","volume":"9","author":"Nardi","year":"2016","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.clml.2017.02.015_bib57","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.humpath.2012.05.003","article-title":"IDH mutations in acute myeloid leukemia","volume":"43","author":"Rakheja","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clml.2017.02.015_bib58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/leu.2011.298","article-title":"Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients","volume":"26","author":"Patnaik","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ajh.23596","article-title":"IDH mutations are closely associated with\u00a0mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution","volume":"89","author":"Lin","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.02.015_bib60","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","article-title":"Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia","volume":"145","author":"Gelsi-Boyer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.02.015_bib61","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-5-12","article-title":"Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases","volume":"5","author":"Gelsi-Boyer","year":"2012","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2017.02.015_bib62","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2010-05-283291","article-title":"Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations","volume":"116","author":"Chou","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib63","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3324\/haematol.2011.051532","article-title":"Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value","volume":"97","author":"Pratcorona","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.02.015_bib64","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nrc2736","article-title":"Polycomb group proteins: navigators of lineage pathways led astray in cancer","volume":"9","author":"Bracken","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2017.02.015_bib65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2017.02.015_bib66","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2017.02.015_bib67","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib68","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/blood-2011-12-397620","article-title":"Loss of heterozygosity in 7q myeloid\u00a0disorders: clinical associations and genomic pathogenesis","volume":"119","author":"Jerez","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib69","doi-asserted-by":"crossref","first-page":"33217","DOI":"10.18632\/oncotarget.5202","article-title":"High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis","volume":"6","author":"Kao","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2017.02.015_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/leu.2016.160","article-title":"Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD)","volume":"31","author":"Sun","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib71","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/blood-2009-11-255976","article-title":"RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis","volume":"117","author":"Schnittger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib72","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3324\/haematol.10869","article-title":"A\u00a0comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia","volume":"92","author":"Bacher","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.02.015_bib73","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/leu.2010.124","article-title":"Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML","volume":"24","author":"Dicker","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib74","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2141.2007.06811.x","article-title":"RUNX1 gene mutation in primary myelodysplastic syndrome\u2014the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome","volume":"139","author":"Chen","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.02.015_bib75","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.015_bib76","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib77","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2010.30.2554","article-title":"Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications","volume":"29","author":"Marcucci","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.015_bib78","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.015_bib79","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.015_bib80","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/leu.2016.163","article-title":"Subtype-specific patterns of molecular mutations in acute myeloid leukemia","volume":"31","author":"Rose","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib81","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib82","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ng.2696","article-title":"Somatic SETBP1 mutations in myeloid malignancies","volume":"45","author":"Makishima","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2017.02.015_bib83","doi-asserted-by":"crossref","first-page":"28914","DOI":"10.18632\/oncotarget.8016","article-title":"Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group","volume":"7","author":"Bresolin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2017.02.015_bib84","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib85","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2017.02.015_bib86","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.23611","article-title":"Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression","volume":"89","author":"Hou","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.02.015_bib87","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/leu.2013.145","article-title":"SETBP1 mutation analysis in 944 patients with MDS and AML","volume":"27","author":"Thol","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib88","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.12491","article-title":"Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression","volume":"163","author":"Fernandez-Mercado","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.02.015_bib89","doi-asserted-by":"crossref","first-page":"14251","DOI":"10.18632\/oncotarget.7350","article-title":"Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS","volume":"7","author":"Kanagal-Shamanna","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2017.02.015_bib90","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/leu.2013.97","article-title":"SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML","volume":"27","author":"Laborde","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib91","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/leu.2013.35","article-title":"SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias","volume":"27","author":"Damm","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib92","series-title":"NCCN Clinical Practice Guideline in Oncology: Myelodysplastic Syndromes, Version 1.2017","year":"2016"},{"key":"10.1016\/j.clml.2017.02.015_bib93","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.leukres.2014.10.006","article-title":"The molecular basis and clinical significance of\u00a0genetic mutations identified in myelodysplastic syndromes","volume":"39","author":"Zhang","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2017.02.015_bib94","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.8023157","article-title":"Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations","volume":"265","author":"Cho","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.clml.2017.02.015_bib95","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/leu.2016.263","article-title":"The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL\u2014an analysis of 3307 cases","volume":"31","author":"Stengel","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib96","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.02.015_bib97","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/sj.leu.2405078","article-title":"Genetics of therapy-related myelodysplasia and acute myeloid leukemia","volume":"22","author":"Pedersen-Bjergaard","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib98","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.leukres.2014.12.006","article-title":"Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases","volume":"39","author":"Ok","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2017.02.015_bib99","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.critrevonc.2015.11.004","article-title":"Myeloproliferative neoplasms: current molecular biology and genetics","volume":"98","author":"Saeidi","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2017.02.015_bib100","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/modpathol.2014.160","article-title":"Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations","volume":"28","author":"Ohgami","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2017.02.015_bib101","doi-asserted-by":"crossref","first-page":"14172","DOI":"10.18632\/oncotarget.7290","article-title":"Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents","volume":"7","author":"Takahashi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2017.02.015_bib102","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tibs.2012.02.009","article-title":"The spliceosome: a flexible, reversible macromolecular machine","volume":"37","author":"Hoskins","year":"2012","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.clml.2017.02.015_bib103","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clml.2017.02.015_bib104","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.015_bib105","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","article-title":"Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia","volume":"124","author":"Malcovati","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib106","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib107","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2011-09-377994","article-title":"SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value","volume":"119","author":"Patnaik","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib108","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajh.23373","article-title":"Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance","volume":"88","author":"Patnaik","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.02.015_bib109","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib110","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2012-05-429696","article-title":"SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival","volume":"120","author":"Lasho","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib111","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1182\/blood-2012-02-412296","article-title":"The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution","volume":"120","author":"Wu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib112","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib113","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","article-title":"Prognostic relevance of FLT3-TKD mutations in AML: the combination matters\u2014an analysis of 3082 patients","volume":"111","author":"Bacher","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib114","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/sj.leu.2403458","article-title":"A\u00a0distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication","volume":"18","author":"Kussick","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.015_bib115","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2017.02.015_bib116","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood-2009-01-198416","article-title":"Mutations in CBL occur frequently in juvenile myelomonocytic leukemia","volume":"114","author":"Loh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib117","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2014-04-567057","article-title":"Genetic alterations of the cohesin complex genes in myeloid malignancies","volume":"124","author":"Thota","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib118","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/ng.2731","article-title":"Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms","volume":"45","author":"Kon","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2017.02.015_bib119","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood-2014-08-550483","article-title":"How I treat juvenile myelomonocytic leukemia","volume":"125","author":"Locatelli","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.015_bib120","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2017.02.015_bib121","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1038\/bcj.2014.94","article-title":"Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia","volume":"5","author":"Lasho","year":"2015","journal-title":"Blood Cancer J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017300277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017300277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:06Z","timestamp":1761870546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017300277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":121,"alternative-id":["S2152265017300277"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.02.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}